CROTF yields 111111.11% · JNJ yields 2.13%● Live data
📍 CROTF pulled ahead of the other in Year 1
Combined, CROTF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CROTF + JNJ for your $10,000?
Spenda Limited develops and commercializes technology assets that enable the modernization of business IT systems through conversion, migration, and management of server-based legacy data and systems to the cloud in Australia. It operates through SaaS and Payments, and Lending segments. The company offers business-to-business payment services; merchant services; solutions for integrating payments into the software platform or marketplace; and invoice, supplier, buyer, and agri finance solutions. It also provides accounts receivable automation software for streamlining collections and accelerating incoming payments; accounts payable automation software for managing supplier payments and driving stronger cash flow; portable point of sale systems; sales order management for collaborating on orders with customers; eCommerce solutions; warehouse management solution for accessing accurate data and managing inventory; workshop management software for managing auto workshops; service management solution for streamlining business from end-to-end and enhance the customer experience with cloud-based field service management solution; and purchasing software, a digital tool designed to automate and optimize procurement processes. The company was formerly known as Cirralto Limited and changed its name to Spenda Limited in February 2022. Spenda Limited is based in North Sydney, Australia.
Full CROTF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.